Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

CSIRO Successful completion of first milestone

Jun 10, 2013AaronNews

In August 2012 MVP announced it had entered into a research and development program with the CSIRO designed to introduce a new, more efficient, significantly lower manufacturing cost process for the pharmaceutical compound used in Penthrox®. We are delighted to announce the first milestone, which is to manufacture commercial grade methoxyflurane in much larger quantities than at present, has been achieved. This is an important milestone for MVP and, should the program conclude successfully, the result will be that MVP will have a world first, proprietary manufacturing process for methoxyflurane, which will increase manufacturing capacity while significantly reducing our cost of goods sold.

Download MVP ASX Announcement PDF

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

  • MVP FY22 Half Year Report and Accounts

    24 February 2022 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter